中国感染控制杂志2026，Vol.25Issue(3)：448-455,8.DOI:10.12138/j.issn.1671-9638.20263072
β-内酰胺类药物皮肤试验的研究进展与政策启示
Research progress and policy enlightenment of skin test for β-lactam drugs
夏玉香 1孙路路 1府裕琦 1陈熙 1赵颖波1
作者信息
- 1. 国家卫生健康委医院管理研究所药事管理研究部,国家药事管理专业医疗质量控制中心,北京 100044
- 折叠
摘要
Abstract
Beta-lactam(β-lactam)drugs are the most widely used antimicrobial agents globally,with significant variations in practice of skin test across different countries.In 2021,China issued relevant guidelines,aiming to promote a transition of skin test mode from routine screening to evidence-based evaluation,but challenges still remain in practical implementation.This review systematically analyzes the practical differences in skin test for β-lactam drugs through comparing domestic and international guidelines and research,exploring the underlying scientific,cultural,and institutional factors,with the aim of providing reference for the implementation of policies and the optimization of antimicrobial stewardship strategies in China.关键词
β-内酰胺类/皮肤试验/循证医学/抗菌药物管理策略/医疗政策Key words
beta-lactams/skin test/evidence-based medicine/antimicrobial stewardship strategy/medical policy分类
医药卫生引用本文复制引用
夏玉香,孙路路,府裕琦,陈熙,赵颖波..β-内酰胺类药物皮肤试验的研究进展与政策启示[J].中国感染控制杂志,2026,25(3):448-455,8.
